MedWatch

Novo Nordisk and Microsoft to collaborate on drug development using AI

The Danish drugmaker’s research and development division gains access to Microsoft’s data and knowledge of artificial intelligence.

Photo: Novo Nordisk / PR/Henning Larsen Architects

On Monday, Novo Nordisk and Microsoft announced in a press release a new strategic collaboration that will combine the pharmaceutical firm’s drug discovery machine with the tech giant’s artificial intelligence and cloud services.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs